Biocytogen published a new study in the Journal of Controlled Release introducing AODC, an antibody-oligonucleotide-drug conjugate approach.
Published
Signal category
Research & Knowledge
Quote
“A new Journal of Controlled Release study introduces AODC: antibody–oligonucleotide–drug conjugates, a conceptually different approach to targeted drug delivery.”
— Fengqian Chen, Ph.D.|Biocytogen team
Company
Biocytogen
Your Partner From Targets To Therapeutics
- Industry
- Biotechnology Research
- Location
- Waltham, US
- Company size
- 229 employees
Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ mice), and in vivo/in vitro preclinical validation studies. Biocytogen collaborates with more than 70% of the top 50 pharmaceutical and biotechnology companies worldwide. Together, we discover innovative medicines for a better, healthier world.
Founded 2009